Pfizer and Ranbaxy petition Supreme Court in Lipitor

Drugmakers accused of a pay-for-delay scheme have asked the US Supreme Court to review an appellate court’s decision that held plaintiffs do not need to calculate patent litigation costs to allege that a drugmaker cut an illegal deal with a generic competitor.

Get unlimited access to all Global Competition Review content